The primary objectives of the trial is to investigate the effect of the use of inhaled colistimethate sodium, administered twice daily via the I-neb for 12 months, compared to placebo in subjects with non-cystic fibrosis bronchiectasis (NCFB) chronically infected with P. aeruginosa on the frequency of pulmonary exacerbations.
|Treatment||Saline solution, Colistimethate Sodium|
|Clinical Study Identifier||NCT03093974|
|Last Modified on||15 November 2020|
Select a piece of text and start making personal notes.
Congrats! You have your own personal workspace now.